Shows
DCAT Value Chain Insights’ Production to Prescription2025: The Bio/Pharma Industry’s Year in ReviewWithout question, evolving US tariff and trade policy was the story of the year, and how such policy will be implemented looms large. At the same time, the normal course of business in the bio/pharmaceutical industry—new drug approvals and the progression of pipelines, including new modalities—was also top of mind.In this special episode of the Production to Prescription podcast, 2025: The Bio/Pharma Industry’s Year in Review, we provide key insights from industry experts and a snapshot of key trends across the bio/pharmaceutical manufacturing value chain that are relevant as the industry moves...
2025-12-1137 minDCAT Value Chain Insights’ Production to PrescriptionWhat’s Trending: ADCs: Pipelines, Products, & CDMO GrowthAntibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights. Support the show
2025-11-0620 minDCAT Value Chain Insights’ Production to PrescriptionDrug Launches & Approvals in 2025: The Blockbuster ContendersWhich bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
2025-10-1617 minDCAT Value Chain Insights’ Production to PrescriptionCDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?What will be the impact of US tariffs on CDMOs of injectables and on the decision-making of pharma companies on in-sourced/outsourced activity overall and in key geographic markets: Europe, Canada, India and China? How will major segments, innovator drug and generics/biosimilar be affected? Featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting, where he focuses on healthcare and life sciences, including pharmaceuticals and vaccines, and leads L.E.K.’s Pharmaceutical Contract Services Practice.Support the show
2025-09-0426 minDCAT Value Chain Insights’ Production to PrescriptionHeadwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, an important barometer of the financial health of the sectors, has been under pressure with macro factors in the US on tariffs, tax & monetary policy, and drug pricing reforms contributing to uncertainty. But will the tide turn?Featuring Arda Ural, EY America Life Sciences Leader, Ernst & Young (EY)Support the show
2025-06-0536 minDCAT Value Chain Insights’ Production to PrescriptionGlobal API Outlook: Will Supply Lines Change Amid Tariff Uncertainty?As evolving US trade policy looms, what are the demand–supply fundamentals now in the global market for active pharmaceutical ingredients (APIs)? A look at the demand side—size, growth rates, and trends— and the supply side—key segments for global API manufacturing and its geographic dispersion. Plus, examining the impact of potential tariffs on manufacturing and supply chains. Support the show
2025-05-0816 minDCAT Value Chain Insights’ Production to PrescriptionBiomanufacturing: How are Industry Capacity & Supply Chains Trending?What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies, and is there too much capacity or is the market tight? Is biomanufacturing outsourcing up or down? Are biopharma companies outsourcing more or less? Plus the impact on evolving trade policy on biomanufacturing supply chains. Featuring: Eric Langer, MBA, Managing Partner & President, BioPlan Associates and Renaud Jacquemart, PhD, MBA, Senior Advisor, BioPlan AssociatesSupport the show
2025-04-0338 minDCAT Value Chain Insights’ Production to PrescriptionParenteral Drug Mfg—CDMO Outlook: a Capacity Crunch of Easing?How are supply and demand shaping up for sterile manufacturing and aseptic fill–finish in the CDMO/CMO sector? Is a capacity crunch or capacity ease in the making? And how will hot-product areas, such as GLP-1 agonist impact market fundamentals. Featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting, where he focuses on healthcare and life sciences, including pharmaceuticals, vaccines, and leads L.E.K.’s Pharmaceutical Contract Services practice. Support the show
2025-02-0627 minDCAT Value Chain Insights’ Production to PrescriptionBio/Pharma Industry Outlook, Supply Chains 2025: The Year AheadWhat will be the key issues shaping bio/pharma supply chains in 2025? Looking at the impact of potential changes in US tariff and trade policy. Plus, what lies ahead in product-specific supply chains for sterile injectables and antibody drug conjugates. And the latest on how companies are advancing upstream supplier risk monitoring and predictive risk planning, including through digitalization and AI. Featuring: Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLPSupport the show
2024-12-3024 min
Comerit "What's Up Enterprise?" PodcastEpisode 21 - You Won't Believe How This Famous Music Producer is Using AIThis week's episode is a mind-blowing interview with Dwane ("DCat") Cornelius, the CEO of DCat Music Company and Just A Minute Music Library, a music publisher, platinum engineer, producer, musician, and entrepreneur! DCat's musical journey is nothing short of legendary. He's toured with iconic artists like Earth, Wind & Fire and Natalie Cole, produced tracks for Snoop Dogg, and collaborated with the legendary George Clinton. 🔥 Watch now to hear DCat share:The music industry's untold technological challenges and opportunitiesDCat's groundbreaking crypto project, Soul JamThe power of AI an...
2024-06-0645 minDCAT Value Chain Insights’ Production to PrescriptionWhat’s Trending: Parenteral Drug Development & ManufacturingWhat are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights takes an inside look. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above) Major trends in parenteral drug development Long peptides in NDAs and BLAs New complex modalities Sterile drug-product capacity market shifts Complex sterile injectables Regulatory issues Digitalization and automation Podcast Sponsor: Vetter Pharma I...
2024-02-2216 minDCAT Value Chain Insights’ Production to PrescriptionCDMOs/CMOs: The Movers and Shakers of 2023As 2023 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2023? DCAT Value Chain Insights looks at which companies topped the headlines this year and the leading moves they made. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above) BaxterSamsung BiologicsLotte BiologicsFujifilm Diosynth BiotechnologiesLonza CambrexExpansions in peptides, oligonucleotides BachemAgilent TechnologiesWuXi STACordenPharmaAjinomotoBain’s acquisition of F.I.S.eureKINGNew CDMOs enter the market Bridgewest Group SynCrest NewBiologix Ascend Gene & Cell Therapies Podca...
2023-12-2127 minDCAT Value Chain Insights’ Production to PrescriptionCDMO/CMO Mid-Year Review: Tracking the Key Moves Thus Far in 2023As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an inside look on what is on the industry’s radar. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) BaxterLarge-scale biomanufacturing expansions continue Samsung BiologicsLotte BiologicsFujifilm Diosynth BiotechnologiesLonza WuXi BiologicsExpansions in Peptides and Oligonucleotides Ramp UpBachemAgilent TechnologiesWuXi STACordenPharmaNew CDMOs Enter the Market eureKINGNewBiologixAscend Gene & Cell TherapiesPodcast...
2023-06-1423 minDCAT Value Chain Insights’ Production to PrescriptionAPI Alert: EU Proposes New Requirements To Secure Pharma Supply ChainsThe European Commission has issued its long-awaited proposal to reform pharmaceutical legislation in the EU, the first major overhaul in 20 years, which includes new requirements to address drug shortages and secure supply chains. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above) Proposed reforms Security of supply and supply-chain reforms Specific proposals Podcast Sponsor: BIOVECTRALinks: Subscribe to our e-newsletter at www.dcatvci.org Follow us on Twitter @DCATvci ...
2023-05-0213 min
House Radio EcuadorHouse Radio Ecuador #63 - Dcat Guest MixDisfruta y comparte.
Sigue a Dcat
https://www.facebook.com/dj.dcat
https://www.instagram.com/dcaaaaat/
Tracklist
0:00 : Faithless - We Come One (Gentech Remix)
2:45 : Push - Strange world (Joyhauser Remix)
5:56 : Karney – Smiler (Nineteen Sines Remix)
10:00 : The Weeknd - Blinding Lights (Mark Sherry Remix)
14:55 : Mark Dekoda - Rave Harder Techno Bass
17:52 : Monika Kruse - Latin Lovers (Greg Downey Rework)
19:56 : Technotronic - Pump Up the Jam (Mark Sherry Remix)
22:58 : Kate Bush - Running Up That Hill (Mark Sherry Remix)
2023-02-1028 minDCAT Value Chain Insights’ Production to PrescriptionThe CDMO/CMO Report: Parenteral DrugsIncreased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain Insights rounds up the latest developments among CDMO/CMOs. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Recent expansion projects Baxter BioPharma Solutions Vetter Recipharm WuXi STA Jubilant HollisterStier PCI Pharma Services Grand River Aseptic Manufacturing Catalent Thermo Fisher Scientific Lonza Carbogen Amcis Alcami Delpharm Fareva WuXi Biol...
2022-11-1630 minDCAT Value Chain Insights’ Production to PrescriptionDrug Products: Key Trends & Recent ApprovalsWhat are noteworthy trends in drug delivery and drug-product development in key dosage forms: solid dosage and parenteral drugs? A look at key technology advances and recent new drug approvals. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above)Recent trends: new drug approvalsTechnology advancesEnable Injections’ on-body subcutaneous drug-delivery systemLilly’s and Triastek’s pact for 3-D printing for oral drug deliveryMultifunctional wireless robots in drug deliveryAdvances in implantable devices for drug delivery Sponsor: Vetter Pharma Interna...
2022-08-1711 minDCAT Value Chain Insights’ Production to PrescriptionCDMOs/CMOs Expand High-Potency API ManufacturingGrowth in the oncology drug market continues to spur demand for high-potency API manufacturing. Which CDMOs/CMOs are expanding? DCAT Value Chain Insights rounds up the latest investments. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above)A roundup of recent investments in HPAPI manufacturing WuXi STA MilliporeSigmaPiramal Pharma SolutionsCambrexHAS Healthcare Advanced SynthesisAGC Fine ChemicalsLonzaCarbogen AmcisSterling Pharma SolutionsAjinomoto Bio-Pharma ServicesNovasepOlonCerbios-PharmaFormosa LaboratoriesSai Life SciencesBSP PharmaceuticalsSeqensCordenPharma Sponsor: BIOVECTRA Links:Subs...
2022-07-1421 min
Molecule to Market: Inside the outsourcing spaceDiaries of DCATLast week marked the return of DCAT in New York City. A prestigious event that’s open to companies engaged in the Biotech and Pharmaceutical manufacturing space…
With the massive return this year of events. Your host, Raman Sehgal, decided to shake things up this year and do things differently, taking your favourite life science podcast Molecule to market with him… Equipped with only a laptop and a microphone, he hit the event space in style and interviewed some great guests along the way.
Listen to a variety of select guests at the top of their...
2022-04-0628 minMolecule to Market: Inside the outsourcing spaceDiaries of DCAT
Last week marked the return of DCAT in New York City. A prestigious event that's open to companies engaged in the Biotech and Pharmaceutical manufacturing space...
With the massive return this year of events. Your host, Raman Sehgal, decided to shake things up this year and do things differently, taking your favourite life science podcast Molecule to market with him… Equipped with only a laptop and a microphone, he hit the event space in style and interviewed some great guests along the way.
Listen to a variety of select guest...
2022-04-0425 minDCAT Value Chain Insights’ Production to PrescriptionIncorporating Sustainability into the Bio/Pharma Supply Chain: Where Does the Industry Stand?A newly released DCAT benchmarking study examines the targets and progress made by bio/pharma companies and suppliers in reaching their sustainability goals. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above)Sustainability and the bio/pharma supply chainKey finding: External stakeholders drive effortsKey finding: Supply-chain sustainability lags internal effortsKey finding: Measuring achievement a major challengeKey finding: Factoring sustainability into purchasing decisions Concluding thoughtsSponsor: LGM PharmaLinks:...
2022-03-3115 min
Machine-Centric ScienceF3: Metadata clearly and explicitly include the identifier of the data they describeLiterature references with and without DOIs. Tables of data in articles with and without unique identifiers in each row for what that row is about. The magic of including identifiers in the metadata you share.The Data Catalog (DCAT) Vocabulary: https://www.w3.org/TR/vocab-dcat-2/
2022-03-1503 minDCAT Value Chain Insights’ Production to PrescriptionCDMOs/CMOs Ramp Up Biomanufacturing CapacityCapital investments are ramping up in biomanufacturing, which continues to be an active area for CDMOs/CMOs in both traditional biologics and new modalities. Which companies are expanding? For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above)A roundup of expansion activityFujifilm Diosynth BiotechnologiesSamsung BiologicsLonzaBoehringer IngelheimThermo Fisher ScientificCatalentWuXi Biologics Sponsor: BIOVECTRALinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the s...
2022-03-1419 minDCAT Value Chain Insights’ Production to PrescriptionHow Can Today’s Supply-Chain Challenges Be Fixed?A DCAT Week program brings together leading Bio/Pharma executives to offer their perspectives on how Bio/Pharma companies and their suppliers are adjusting supply practices now and in the near term. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Supply-chain challenges and solutions (1:13)Sponsor: LGM PharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the showSupport the show
2022-03-0705 minDCAT Value Chain Insights’ Production to PrescriptionParenteral Drugs: CDMOs/CMOs ExpandingParenteral drugs have accounted for between 40% and 50% of new drug approvals over the past five years. CDMOs/CMOs continue to expand. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers in drop down menu in audio player above)Active area of investment (1:13)Baxter BioPharma Solutions (1:25)PCI Pharma Services (2:07)Alcami (3:22)Catalent (4:31)Vetter (5:47)Thermo Fisher Scientific (6:41)Grand River Aseptic Manufacturing (7:35)Lonza (9:12)Curia (9:50)Jubilant HollisterStier (10:22)Carbogen Amcis (10:53)Fareva (11:46)BSP Pharmaceuticals (12:43)Recipharm (13:33)Aenova (15:01)Wuxi Biologics (15:42)Samsung Biologics (16:08)Ajinomoto Bio-Pharma Services (16:44)Selkirk Pharma (17:07)Sponsor: Vetter Pharma International GmbH
2021-11-1518 minDCAT Value Chain Insights’ Production to PrescriptionRising Energy Costs and API SupplyEscalating energy prices are impacting global manufacturing and supply chains. In the EU, leaders are proposing measures to alleviate pricing pressures. What’s the plan?Key topics: (see Chapter Markers)Economic recovery brings pricing pressuresRising energy costs and the bio/pharma manufacturing value chain Rising energy costs: call for action in the EU Ripple effect throughout industrial supply chainsActions proposed by the European CommissionProposals for energy-price reliefSponsor: LGM PharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twit...
2021-10-2517 min
KZMU Public AffairsThis Week in Moab – Sustainable Development and the 'Power of the Code'On the latest This Week in Moab, a discussion about the housing crisis, and the ways building codes and development norms frequently undermine efforts to address the issues, while adding to climate woe. Host Christy Williams-Dunton speaks with David Eisenberg of the Development Center for Appropriate Technology (DCAT) in Tucson, Arizona. They discuss the 'power of the code' to address not just the housing crisis, but the climate crisis too, and how to give regulatory shape to sustainable development models. Eisenberg visited Moab recently as part of the Natural Building Alliance’s 2021 Rocky Mountain Natural Building Conference.
Show Notes:
Development Ce...
2021-10-2348 minDCAT Value Chain Insights’ Production to PrescriptionBlockbuster Muscle: Small Molecules or Biologics?Which modality, small molecules or biologics, leads among the top-selling products? A look at the top-selling products industry-wide and blockbusters from select leading bio/pharma companies provides the answer. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Modality of top-selling productsNew drug approvals: small molecules versus biologicsPotential blockbusters: small molecules and biologicsBiogen’s and Eisai’s aducanumabArgenx’s efgartigimodBristol-Myers Squibb’s mavacamtenUCB’s bimekizumabBristol Myers Squibb’s/bluebird bio’s idecabtagene vicleucel (ide-cel)Ascendis Pharma’s TransCon hGH (lonapegsomatropin)Sponsor: LGM PharmaLinks:...
2021-09-0714 min
Penn State Supply Chain PodcastEpisode 5 - Diversity, Equity, and InclusionThis month's guest, Rakhi Agarwal, Franchise Engagement Leader at Johnson and Johnson's Janssen Supply Chain, shares that, "The right pool of talent can only come if you build diversity into the fabric and DNA of the organization." While most supply chain organization's recognize the value and importance of diversity among supply chain talent, how to build a culture of diversity, equity and inclusion can be less clear. Rakhi shares advice for organizations who wish to start, build, and maintain a culture that leverages diversity. She shares how we can all become agents of change and how our personal commitment to...
2021-08-3128 minDCAT Value Chain Insights’ Production to PrescriptionInjectable and Solid Dosage Drug Delivery: Key DealsDrug delivery is important not only for ensuring bioavailability for therapeutic benefit but also for product differentiation and market success. DCAT Value Chain Insights highlights technology advances in drug delivery for injectable and solid-dosage drugs and other products from recent start-ups, partnering deals, and mergers and acquisitions. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Mergers and acquisitionsPartneringStart-upsNew strategy/managementSponsor: Vetter Pharma International GmbHLinks:Subscribe...
2021-08-1312 minMolecule to Market: Inside the outsourcing space2021 mid-year CDMO Review: COVID-19 Vaccine Manufacturing and M&AIn today’s special ‘bite-sized’ Molecule to Market episode, I’ll be talking with Jim Miller about the CDMO space at the half point mark in 2012.
Inspired by this terrific article https://www.dcatvci.org/7173-mid-year-cdmo-review-covid-19-vaccine-manufacturing-and-m-a on the DCAT ValueChain Insights websites, Jim covers:
Vaccine manufacturing, capacity constraints and the increasing scale and role of the CDMO in the pharma space.
32+ M&A deals already and an outlook for more (and bigger) activity on the cards.
Very encouraging trends for CDMOs in terms of funding in the sector, likely preparation for future pandemics and a backlog of...
2021-06-2332 minDCAT Value Chain Insights’ Production to PrescriptionMid-Year CDMO Review: COVID-19 Vaccine Manufacturing and M&AWhat have been the key developments in 2021 thus far in the CDMO market? In this podcast we take a look at the increasing participation by CDMOs in COVID-19 vaccine manufacturing and robust mergers and acquisition activity that have marked the first half of 2021. What are the implications, and what can be expected going forward? For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)CDMOs and COVID-19 vaccine manufacturingPotential implications of increased injectables capacityCDMO M&A remains robustCell and gene therapies: a major source of CDMO M&APrivate equity...
2021-06-1116 minDCAT Value Chain Insights’ Production to PrescriptionFDA Addresses Supply Constraints Due to COVID-19; Plus, Packaging Suppliers ExpandFDA Addresses Supply Constraints Due to COVID-19; Plus, Packaging Suppliers Expand In this podcast we take a look at the FDA’s new guidance to facilitate changes to container-closure-system components due to supply constraints, plus updates from suppliers of materials used to deliver COVID-19 vaccines, treatments and other parenteral drugs. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)FDA addresses supply constraintsSuppliers increase production Sponsor: Vetter Pharma International GmbH Links:Subscribe to our e-newsletter at ww...
2021-03-1211 minDCAT Value Chain Insights’ Production to PrescriptionThe Year in Review: 2020Although the COVID-19 pandemic dominated the headlines in 2020, there were other key developments in 2020. In this year in review, we look at the other key developments in 2020, including new product approvals, noteworthy deals, and other developments making the news. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)2020 in Review: The Top 10 Developments1. Volume growth of pharmaceuticals declines globally.2. New molecular entities approvals by FDA keeps pace with prior years.3. The new AbbVie: AbbVie’s $63-Bn acquisition of Allergan.4. Viatris launch...
2020-12-0421 minDCAT Value Chain Insights’ Production to PrescriptionCompany on the Move: ViatrisIn this podcast we feature an article about what and who is behind Viatris, the new company formed from the combination of Upjohn, Pfizer’s off-patent branded and generic established medicines business, and Mylan. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Rationale for the new companyInside the new Viatris: productsInside the new Viatris: manufacturingInside Viatris: leadership, company structure, and cost-savings planSponsor: LabVantage SolutionsLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on...
2020-11-2013 minDCAT Value Chain Insights’ Production to PrescriptionSolid-Dosage Mfg: CDMO Market and Product TrendsIn this podcast we feature an article that looks at solid dosage manufacturing in terms of CDMO growth rates and recent product trends. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)New drug approvals and solid-dosage productsCDMOs/CMOs: inside the numbersRecent facility acquisitions among solid-dose CDMOs/CMOsOther expansionsCatalentLonzaMetrics Contract ServicesNextPharmaThermo Fisher ScientificLGM PharmaFrontida BioPharmAdare PharmaceuticalsCoreRxVelesco PharmaUpperton Pharma SolutionsSponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter...
2020-11-0523 minDCAT Value Chain Insights’ Production to PrescriptionTop 10 Watch List: Pharma CEOs on the RiseIn this podcast we feature a list of the Top 10 pharma CEOs to watch in 2020. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Pharma CEOs to watch in 20201. Three-way tie: Pfizer, J&J, and AstraZeneca.Pfizer Chairman and CEO Albert BourlaJ&J Chairman and CEO Alex GorskyAstraZeneca CEO Pascal Soriot4. Moderna CEO Stéphane Bancel5. Gilead Sciences Chairman and CEO Daniel O’Day6. Regeneron Pharmaceuticals Co-Founder, President and CEO Leonard S. Schleifer7 (tie). CureVac CEO Franz-Werner Haas and Novavax CEO and President Stanley C. Erck9. Seagen (formerly Sea...
2020-10-2318 minDCAT Value Chain Insights’ Production to PrescriptionThe Pipeline Contenders: What Drugs Are Making the Mark?In this podcast we feature an article that looks at some key upcoming developments from the pipelines of the large pharmaceutical companies for new drugs or existing drugs with new indications with blockbuster potential. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Inside Big Pharma’s pipelineAbbVieAmgen/AstraZenecaAstraZenecaBristol-Myers SquibbEli Lilly and CompanyGlaxoSmithKlineRocheSponsor: Vetter Pharma International GmbHLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show (ht...
2020-10-0912 minDCAT Value Chain Insights’ Production to PrescriptionInjectable Drugs: CDMOs/CMOs and Suppliers ExpandIn this podcast we feature a roundup of up expansions by CDMOs/CMOs and other suppliers in injectable drug development and manufacturing. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Injectable drugs and recent drug approvalsManufacturing expansions and technology advancesA roundup of CDMO/CMO expansions thus far in 2020VetterCatalentGrand River Aseptic ManufacturingCordenPharmaAlcamiThermo Fisher ScientificRecipharmSamsung BiologicsPCI Pharma ServicesWuXi BiologicsBushu PharmaceuticalsEvonikLSNE Contract ManufacturingBerkshire Sterile ManufacturingIntegrity BioArgonaut Manufacturing ServicesSuppliers of packaging materials and components for injectable drugs expandCorningStevanato GroupSchottWest Pharmaceutical ServicesSponsor: Vetter Pharma International GmbH
2020-09-1828 min
Whose Review Matters Anyway?DCaT Talks MulanWe discuss the newest Disney live-action remake Mulan. Afterward, we discuss the latest Mario Direct and its major announcements.
2020-09-071h 25DCAT Value Chain Insights’ Production to PrescriptionAPI Watch: Small MoleculesIn this podcast we feature an article that looks at the small molecules approved as new molecular entities thus far in 2020 and which have blockbuster potential. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Small-molecule new drug approvals thus far in 2020Small molecules and blockbuster potentialNovo Nordisk’s RybelsusBristol-Myers Squibb’s Zeposia Novartis’ inclisiranGilead Sciences’ filgotinib Akebia Therapeutics’, Mitsubishi Tanabe Pharma’s, and Otsuka Pharmaceutical’s vadadustat Biohaven Pharmaceuticals’ Nurtec Sponsor: Dr. Reddy’s LaboratoriesLinks:Subscribe to our e-newsletter at www...
2020-09-0419 minWhose Review Matters Anyway?DCaT Face the MusicWe talk about the newest Bill & Ted addition Face the Music. We also discuss a couple of controversial issues surrounding Marvel and Disney.
2020-09-041h 07Whose Review Matters Anyway?Lost Episode: DCaT's Most Excellent AdventureWe didn't publish this episode last Friday. We apologize. So we decided to at least publish the first half of the episode where we talk about Bill and Ted 1 & 2. Hear our thoughts on these movies before we talk about the third entry Bill and Ted Face the Music.
2020-09-0330 minWhose Review Matters Anyway?The New DCaTWe finally get the opportunity to see The New Mutants. Find out if we thought it was worth the wait, hear a little bit about our movie-going experience, and we talk some news headlines popping up on social media.
2020-09-011h 05Whose Review Matters Anyway?The One and Only DCaTWe talk about the latest Disney + Original movie: The One and Only Ivan. Then we get into a lengthy discussion covering the big hits from the DC Fandome Event.
2020-08-261h 38DCAT Value Chain Insights’ Production to PrescriptionThe Top 10 Deals for Pharma InnovationIn this podcast we feature the top 10 deals thus far in 2020 and which pharma/biopharma companies are rising to the top. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)1. Novartis’s $9.7-billion acquisition of The Medicines Company and Blackstone’s $2-billion investment in Alnylam Pharmaceuticals.2. Daiichi Sankyo’s and AstraZeneca’s $6-billion ADC collaboration. Pairing3. Gilead Sciences’ $4.9-billion acquisition of Forty Seven Inc.4. Genmab’s $3.9-billion cancer antibody pact with AbbVie.5. Sanofi’s pending $3.69-billion acquisition of Principia Biopharma.
2020-08-2418 minWhose Review Matters Anyway?The DCaT CollectorWe take a look at David Ayer's newest movie The Tax Collector. We then look into some updates on some recent gaming headlines.
2020-08-211h 02Whose Review Matters Anyway?DCaT PowerWe talk about the latest entry in the superhero genre (maybe) - Project Power. Afterward, we cover some recent gaming updates and AMC selling 15 cent tickets.
2020-08-181h 06Whose Review Matters Anyway?DCaT Infinite 2077We discuss a major announcement from 343 Industries and talk about some of the latest info about Cyberpunk 2077.
2020-08-141h 14Whose Review Matters Anyway?Deep Blue DCaTIn honor of Shark Week, we take a look into the newest shark movie: Deep Blue Sea 3. Afterward, we cover some recent headlines in gaming.
2020-08-1258 minDCAT Value Chain Insights’ Production to PrescriptionNovel Excipients: Gaining Traction in the IndustryIn this podcast we feature an article that outlines the FDA’s proposed pilot program for the evaluation of novel excipients and summarizes industry feedback on the review program. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Novel excipients and the FDAFDA’s view of a possible novel excipient review pilot programIndustry feedbackLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSponsor: LabV...
2020-08-1020 minWhose Review Matters Anyway?DCaT Chooses Playstation over SharksThis is a long episode, listeners. In the first half of the episode, we discuss the most recent Playstation State of Play event. In the second half, the teacher discusses his heartbreak and concerns about the Spider-Man exclusivity announcement and the group discusses the pros and cons of Mulan coming to Disney Plus VOD.
2020-08-071h 53Whose Review Matters Anyway?DCaT Joins the War for CybertronWe discuss the newest addition to the Transformers franchise, Transformers: War for Cybertron and reflect on those "wonderful" Michael Bay Transformers films.
2020-08-041h 10Whose Review Matters Anyway?DCaT becomes ImmortalWe discuss a recent Netflix release called The Old Guard. Afterwards, we go over a couple Xbox headlines and wonder why recent virtual cons didn't succeed as we initially predicted.
2020-08-011h 13Whose Review Matters Anyway?DCaT is Not Available on Xbox Games PassDCaT breaks down first thoughts/impressions of the X-Box Games Showcase including an in-depth discussion of Halo Infinite.
2020-07-281h 41Whose Review Matters Anyway?DCaT Talks HeadlinesWe take the time to go over a ton of headlines we neglected over the past couple of weeks.
2020-07-241h 16Whose Review Matters Anyway?DCaT Discusses Peacock and DeathgroundWe give an overview of the new streaming service, Peacock. We talk about three of its exclusive original series and share out impressions of them. Afterward, we discuss an interesting survival horror game: Deathground.
2020-07-211h 29Whose Review Matters Anyway?DCaT is IrresistibleDCaT talks about Steve Carell's Irresistible and the bit of politics around it. We cover some recent headlines concerning the launch of Peacock and a new Star Wars animated series coming to Disney +.
2020-07-171h 10Whose Review Matters Anyway?DCaT Goes All Hands on Deck with Greyhound and UbisoftWe discuss Tom Hank's recent movie Greyhound which premiered on Apple TV. We then go into a lengthy discussion of Ubisoft's recent games event.
2020-07-141h 18Whose Review Matters Anyway?DCaT Meets BeckyWe finally get around to watching Becky, the latest horror/thriller starring Kevin James. We then discuss a couple of recent movie trailers and speculate about the Xbox Games Showcase.
2020-07-101h 02DCAT Value Chain Insights’ Production to PrescriptionRe-configuring Global Pharma Supply ChainsIn this podcast we feature an article that looks at the policy debate to repatriate and increase domestic drug manufacturing in the US in light of the COVID-19 pandemic and pharmaceutical supply-chain vulnerabilities. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)A plan for addressing supply-chain vulnerabilities in the USLegislative proposals in the USLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show
2020-07-1017 minWhose Review Matters Anyway?DCaT Is Not Throwing Away their ShotWe talk about our thoughts on Disney + new addition to its library, Hamilton. Afterward, we cover several headlines including an opportunity to play demos of upcoming new days.
Update: Xbox Games Showcase will be on July 23rd at noon EST
Update #2: Our episode closing was cut off for some reason. This isn't the first time. The investigation begins!
2020-07-071h 20Whose Review Matters Anyway?The Last of DCaT Part 2: Our Thoughts on the StoryThis will not be the most organized discussion but we let out what we all thought of the story to The Last of Us Part 2. These are our own opinions. Let us know what you guys think of the game.
2020-07-031h 28Whose Review Matters Anyway?The Last of DCaT: The GameplayWe finally get to start talking about The Last of Us Part 2. However, this will take two episodes. The second episode releasing on Friday will be about the story. Today's episode will be all about the gameplay and the mechanics we come across. Sit back. Relax. Grab a drink. Hear our thoughts about this widely debated game.
2020-06-291h 43DCAT Value Chain Insights’ Production to Prescription2020 Vision: Digital Pharma—Beyond the PillIn this podcast we feature an article that explores the future of digital medicines. For a text version of this article, visit dcatvci.org.Key topics: (see Chapter Markers)Digital medicines and digital healthDigital health and digital medicines: a market viewPharma industry and digital health and digital medicinesLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show
2020-06-2910 minWhose Review Matters Anyway?DCaT Should Have Never Watched This MovieDCaT briefly discusses their most recent watch: You Should Have Left, wishing we had followed that piece of advice. In our headlines, we can get into an interesting discussion about AAA games and their value and cost.
2020-06-2653 minDCAT Value Chain Insights’ Production to PrescriptionA Top 10 Emerging Pharma Watch ListIn this podcast we feature DCAT Value Chain Insights’ Top 10 Emerging Pharma Watch List based on recent high-value partnering deals. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Emerging pharma strength1. Roivant Sciences2. Sangamo Therapeutics3. Silence Therapeutics4. Innovent Biologics5. Arcus Biosciences6. MorphoSys7. Evox Therapeutics8. Accent Therapeutics9. Enleofen Bio10. SitryxLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show
2020-06-2226 minWhose Review Matters Anyway?DCaT Becomes the Kings of Staten of IslandWe discuss the latest movie to hit VOD: The King of Staten Island. We also talk a little bit about new movie and videogames news.
2020-06-2257 minWhose Review Matters Anyway?DCaT Takes a Snap at Artemis FowlWe discuss the latest Disney to hit its streaming service: Artemis Fowl. Afterwards, we breakdown the most recent Pokemon Presentation that came with a couple of surprises.
2020-06-1959 minWhose Review Matters Anyway?DCaT Goes on a Journey to Catch Them AllWe discuss the latest Pokemon series to debut on Netflix: Pokemon Journeys The Series. We also talk about a couple movies getting pushed back again and EA's tease of a new Star Wars game.
2020-06-151h 03Whose Review Matters Anyway?DCaT Reviews the First Pokemon Movie and Its Remake Like No One Ever DidWe remember our first impressions of Pokemon The First Movie and it's recent remake Pokemon Mewtwo Strikes Back Evolution.
2020-06-1257 minDCAT Value Chain Insights’ Production to PrescriptionCDMOs Step Up to the COVID Challenge but Must Prepare for Uncertain FutureIn this podcast we feature an article that looks at the near-term and long-term impact of the COVID-19 pandemic as biopharma companies re-access drug-development projects. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)The CDMO industry in the wake of COVID-19Near-term outlookMedium-term could be challengingLonger-term implicationsLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show
2020-06-1112 minWhose Review Matters Anyway?DCaT Talks about their Favorites in Movies and VideogamesWe take a break from reviewing and discuss our favorites in movies and videogames.
2020-06-0849 minWhose Review Matters Anyway?DCaT Gambles with Uncut GemsWe discuss the big buzz on Netflix which is Uncut Gems starring Adam Sandler. We also talk about Marvel regaining rights to Netflix characters and outline the Pokemon Sword and Shield DLC trailer.
2020-06-051h 00DCAT Value Chain Insights’ Production to PrescriptionTracking Expansion in High-Potency ManufacturingIn this podcast, we round up key recent expansions in high-potency manufacturing by CDMOs and CMOs. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Expansions in high-potency manufacturingLonzaWuXi AppTecSeqensCambrexPiramal Pharma SolutionsCordenPharmaFlammaCerbios-PharmaEvonikAGCNovasepAjinomoto Bio-Pharma ServicesBSP PharmaceuticalsPCI Pharma ServicesSterling Pharma SolutionsHeraeusProcosLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show
2020-06-0415 minWhose Review Matters Anyway?DCaT Calls Upon the Space Force to Defend JacobWe discuss our first impressions of the new Netflix Comedy series Space Force starring Steve Carell. We also go to a bit in-depth about the finale to Defending Jacob. Lastly, we talk about a few videogame headlines as well as discuss the announcement of the PS5 event on Thursday at 4:00 p.m. EST.
2020-06-011h 06Whose Review Matters Anyway?DCaT Goes to the Oscars with ParasiteDCaT breaks down Parasite, an Oscar-winning movie. We talk about several of the intricacies involved and our headlines, afterwards, include Last of Us Part 2 and a few new movie updates including one from The New Mutants.
2020-05-311h 17DCAT Value Chain Insights’ Production to PrescriptionDCAT Benchmarking Study Provides Insight into Supply-Chain ChallengesIn this podcast, we feature an article about a recent DCAT Benchmarking study, conducted prior to COVID-19, that provides insights on whether biopharma companies and their suppliers believe the deteriorating trade environment is a major threat, and what they are doing to confront the real and potential risks to their supply chains. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Examining trade-related risksStudy's backgroundSources of supply-chain riskAwareness of supply-chain riskManaging supply-chain risksUS market scenariosVulnerable industry supply chainsLinks:Subscribe to our e-newsletter...
2020-05-2814 minDCAT Value Chain Insights’ Production to PrescriptionPharma Company on the Move: The New AbbVieIn this podcast, we feature an article that examines the new AbbVie, including the key products and expanded manufacturing networking, resulting from its recent acquisition of Allergan. For a text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Inside the dealInside the new AbbVieLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show
2020-05-2210 minDCAT Value Chain Insights’ Production to PrescriptionRe-inventing US Pharma Mfg and Supply ChainsIn this podcast, we feature an article about the Association for Accessible Medicines’ blueprint to facilitate a repatriation of pharma manufacturing to the US. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)A plan for re-inventing the US pharma supply chainsA proposal for increasing US-based manufacturing for high-priority medicinesList of essential medicines and assessment of the supply chainIncentives for securing the US pharma supply chainLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvci...
2020-05-1514 minDCAT Value Chain Insights’ Production to PrescriptionSupplying Potential COVID-19 Treatments & VaccinesIn this podcast, we outline the manufacturing strategies and alliances that are in play to develop and supply treatments and vaccines against COVID-19? For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Inside the numbers: tracking potential treatments and vaccinesSupply lines for potential COVID-19 drugs and vaccinesThe supply lines: vaccinesRamping up production for potential COVID-19 drugsSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show
2020-05-1321 minWhose Review Matters Anyway?DCaT Discusses the Inside XBox Event and the Biggest Disappointment From ItDCaT breaks down their opinions of the Inside XBox Event and talks about the pros and cons of each game featured. We also discuss the biggest disappointment of the event and ponder on what the next move needs to be to us engaged in the next-gen games.
2020-05-111h 10Whose Review Matters Anyway?Deleted Scenes: DCaT Discusses the AMC/Regal/Universal Dispute and Review Into the Spider-VerseDCaT chimes in with who we stand in the argument between AMC/Regal and Universal. We provide our review of Into the Spiderverse and explain why we left it out of our initial Spider-Man review.
2020-05-0630 minWhose Review Matters Anyway?DCaT Celebrates Star Wars Day and Discusses The MandalorianDCaT brings many news to keep you informed of what you can do on May the 4th to celebrate anything and everything Star Wars. We also discuss The Mandalorian and the Cop comes to terms with his obsession with baby Yoda.
2020-05-041h 12DCAT Value Chain Insights’ Production to PrescriptionDrug Development in Wake of COVID-19In this podcast, we feature an article that examines the effect of COVID-19 on drug development, clinical trials, regulatory review, and new drug approvals. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Drug development and regulatory reviewFDA’s perspectiveNew drug approvals thus far in 2020Clinical trials and COVID-19: where the impact residesCompanies adjust clinical-trial research strategiesSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the sho...
2020-05-0116 minWhose Review Matters Anyway?DCaT Expresses their Satisfaction with My Spy *blinks excessively*DCaT expresses how they really feel about My Spy, and we get into a bit of a debate about Drive-Ins and what would bring us back into the movie theaters.
Instagram: drunk_cop_teacher
Gmail: drunkcop.ateacher@gmail.com
2020-04-281h 21DCAT Value Chain Insights’ Production to PrescriptionA Top 10 Watch List: Biologics and BiomanufacturingIn this podcast we feature DCAT Value Chain Insights’ Top 10 Watch List for Biologics and Biomanufacturing. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Vaccines: the race for a vaccine against the novel coronavirus.Vaccine manufacturing: technology and scale-up.Biologic-based antivirals against the novel coronavirus.Head of the class: the top-selling biologics.Biologics’ share of new drug approvals.Biosimilars: new market entrants.Biosimilars and interchangeability: the market impact.Cell and gene therapies: manufacturing investments.Advances in biomanufacturing.Live biotherapeutic products: a new opportunity. Sponsor: Corden...
2020-04-2721 minWhose Review Matters Anyway?DCaT Goes on a World Tour with some TrollsListen to DCaT discuss and even argue about Tolls: World Tour. We also clarify if Netflix is really making more money than Disney, and we discuss our favorite movie soundtracks.
Instagram: drunk_cop_teacher
Gmail: drunkcop.ateacher@gmail.com
2020-04-241h 13Whose Review Matters Anyway?DCaT Takes a Journey Onward and Remembers to do a Barrel RollDCaT reviews Disney Pixar's latest release Onward and finds out that there are more meaningful messages than spells casted in this movie. We then discuss a few major headlines from the past week from the death of Rick May to an exciting new development behind Doctor Strange 2. Hear us also rant about Comcast's missed opportunity of success for their own streaming service.
2020-04-211h 07DCAT Value Chain Insights’ Production to PrescriptionFacilitating Sourcing in the Wake of COVID-19What measures are being taken by European Union authorities to mitigate potential shortages stemming from supply-chain and manufacturing disruptions? In this podcast we feature an article that outlines the guidance issued by EU authorities to provide flexibility in sourcing for crucial medicines for the treatment of COVID-19. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Providing regulatory flexibility for sourcing activitiesThe exceptional change-management processOther measures in the EU to mitigate drug shortagesSponsor: CordenPharmaLinks:Subscribe to our e...
2020-04-1712 minWhose Review Matters Anyway?DCaT Tackles the Marvel Cinematic Universe: Phase 3 (Part 1)DCaT Tackles the Marvel Cinematic Universe: Phase 3 (Part 1)
2020-04-151h 28DCAT Value Chain Insights’ Production to PrescriptionCOVID-19's Impact on Global Pharma Supply ChainsWhat impact is COVID-19 having on pharmaceutical supply chains? In this podcast, we feature an article that reports on the concerns raised by industry groups, including reduced availability of international air transportation and increasing costs for shipping medicines into the US. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Industry groups weigh in on supply-chain concernsInternational air transportation availability and costsRepatriation of pharmaceutical manufacturing back to the USPotential supply disruptions of drugs identified as potential treatments against COVID-19Prescription refills Sponsor: CordenPharma
2020-04-0613 minDCAT Value Chain Insights’ Production to PrescriptionIndian Government Looks to Increase Domestic API ManufacturingIn this podcast, we feature an article that looks at the Indian government’s $1.3-billion multi-year plan to increase domestic production of key starting materials and active pharmaceutical ingredients and its potential impact on global supply chains. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)India and pharmaceuticals: short termIndia and pharmaceuticals: longer termSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter @DCATvciSupport the show
2020-03-2710 minDCAT Value Chain Insights’ Production to PrescriptionDrug Supply Chains and US-Based ManufacturingWhat does the global nature of the pharmaceutical supply chain mean for US policy? In this podcast, we feature an article that looks at proposals from members of Congress and the federal government to incentivize domestic drug manufacturing in the US. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Global pharmaceutical supply chainsProposals for encouraging US-based pharmaceutical manufacturingOther legislative proposalsExecutive actionSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at www.dcatvci.orgFollow us on Twitter...
2020-03-2315 minDCAT Value Chain Insights’ Production to PrescriptionBlockbuster Watch for 2020: New Market EntrantsWhat are the new blockbuster medicines to watch? In this podcast we feature an article that examines the eleven medicines projected to enter the market in 2020 and achieve blockbuster status by 2024, according to a recent analysis by Clarivate Analytics’ Cortellis Forecast Team. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Blockbuster watch: Big PharmaNovo Nordisk’s Rybelsus (semaglutide)AstraZeneca’s and Daiichi Sankyo’s Enhertu (fam-trastuzumab deruxtecan-nxki)Immunomedics’ sacituzumab govitecanBristol-Myers Squibb’s liso-cel (or lisocabtagene maraleucel),Bristol-Myers Squibb’s ozanimodNovartis’ ofatumumab (subcutaneous)Novartis’ inclisiranGilead Sciences’ filgotinibAkebia Therapeutics’, Mitsubishi Tanabe Phar...
2020-03-0321 minDCAT Value Chain Insights’ Production to PrescriptionOrphan Drugs: Bearing Revenue Gains or Not?Over the past several years, orphan drugs have accounted for more than 40% of new drug approvals by the FDA. In this podcast, we showcase an article that explores whether they are producing the revenue gains pharma companies are seeking or if they are too niche? For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Inside new drug approvals and drug-development trends for orphan drugsInside the market for orphan drugsMarket outlook for orphan drugsOrphan-drug NMEs and market penetrationSponsor: CordenPharmaLinks:
2020-02-2515 minDCAT Value Chain Insights’ Production to PrescriptionEmerging Biopharma Companies: Tracking Their Contribution to InnovationTo what extent do emerging pharma companies contribute to the pharmaceutical industry’s pipeline and new product growth? In this podcast, we showcase an article examining a recent report by IQVIA that analyzes emerging bio pharma companies’ contribution to innovation. For the text version of this article visit dcatvci.org.Key topics: (see Chapter Markers)Inside the numbersInside emerging biopharma companiesEmerging biopharma companies and larger companiesEmerging biopharma companies and therapeutic focusEmerging biopharma companies and commercial productsSponsor: CordenPharmaLinks:Subscribe to our e-newsletter at dcatvci.org...
2020-02-1416 minDCAT Value Chain Insights’ Production to Prescription20-20 Insights and Outlook for the CDMO MarketThe conditions are favorable for another strong year of performance for CDMOs. In this podcast, we showcase an article written by Jim Miller, Consultant and Content Advisor at DCAT, that examines industry fundamentals and an outlook for pharma outsourcing in 2020. For the text version of this article go to dcatvci.org.Key topics: (see Chapter Markers)Strong fundamentals but some risk Mergers and acquisitions: what may be ahead Big Pharma restructuring Upbeat outlook Sponsor: CordonPharmaLinks:Subscribe to our e-newsletter at dcatvci.orgFollow us on Twi...
2020-02-1414 min
Chaos Computer Club - archive feed (high quality)Wikidata and Open Government (Meta)Data - A missing link? (wikidatacon2017)Open Government Data - the open publication of administrative data by governments - is no longer in its infancy. While many governments and subnational regions around the world are beginning to publish their data in open formats, many aspects of the process can be improved. Specific data is usually hard to find and it remains a challenge to link and connect the information already available. As a result, the extent to which the available data is reused remains limited. Hence, governments have turned to the potential of linked open data. Currently, the EU prescribes DCAT-AP as the European Standard to...
2017-10-2823 min
Outsourcing-Pharma PodcastTime of rapid change in fine chemicals supply, says SAFCTom Beil, SAFC’s VP of Quality and Regulatory affairs, whose talk on fine chemicals supply was a highlight of last month's DCAT week, spoke with in-PharmaTechnologist about the benefits and risks of working with global suppliers.
2009-04-0704 min